Global TCR-Based Antibody Market Based on Target Antigen: (NY-ESO-1, p53, WT-1, EBv) Based on Indication: (Bladder Cancer, Multiple Myeloma) Based on End-Users: (Hospitals, Specialized Clinics, Gene Therapy Centers) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

TCR-Based Antibody Market Overview:

The global TCR-based antibody market is projected to reach a valuation of USD 12,865.51 Mn by 2032 at a CAGR of 15.20%, from USD 3,125.38 Mn in 2022.

TCR-based antibodies are genetically modified to specifically target tumor cells. They combine Monoclonal Antibody’s ability to recognize and destroy tumor cells with TCR’s ability to activate and recruit T-cells. TCR-based antibodies can be used as a diagnostic tool to identify specific biomarkers, as well as a therapy alternative to stimulate T-cell attacks on tumor cells. It’s a type of immunotherapy in which a patient’s T-cells are genetically modified to have receptors that target cells in the body that have specific biomarkers.

This sort of treatment is used to treat cancers that haven’t responded to prior treatments or when cancer has progressed. TCR-based antibodies can be made for any protein found on a cell’s outer surface. TCR-Based Antibodies are self-assembling entities that produce an immune response when combined with their appropriate antigen. It is a type of passive immunotherapy that has been found to be effective in the treatment of melanoma. Antibodies are cloned from antigen-specific T-cells in autoimmune disease patients who have been treated with monoclonal antibodies, which then induce an immune response against their antigens.

The TCR-based antibody is a novel, cutting-edge technology that consists of engineered T-cells that can be used as an alternative to traditional antibodies. The first type of these antibodies has been developed for the treatment of cancer by stimulating the body’s immune system to attack tumor cells. Recently, scientists have created this new type of antibody that attacks other types of cancers. A TCR-based antibody is a type of immunoglobulin that has been engineered to mimic not only the specificity of a natural antibody but also its affinity and avidity for antigen. TCR-antibodies are created through research & development and can be used as an alternative treatment for cancer or autoimmune diseases like Alzheimer’s disease.

Global TCR-Based Antibody Market Revenue (USD Mn), 2021–2031:

Recent research in the field of immunology has found that T-cells can be activated to produce antibodies when they are stimulated by a peptide-major histocompatibility complex (pMHC), which is combined with an antigen. This was studied and recognized as TCR-based antibody production. The driving factors for this type of antibody production include the regional variations in the expression levels of TCRs, the positional effects on TCR expression, and self-antigen recognition.

The market for TCR-based antibodies isn’t just a treatment for cancer patients. Rheumatoid arthritis, multiple sclerosis, sepsis, and asthma are just a few illnesses that can be treated with the help of these antibodies. The use of TCR-based antibodies as an efficient and less expensive technique to detect and monitor diseases has recently boosted the market for TCR-based antibodies. As a more efficient and less expensive means to detect and monitor diseases, the TCR-based antibody market is expected to index substantial growth over the projected timeline. Increased research funding, increase in immunotherapies, high demand for therapeutic antibodies, as well as technological advancements in medicine, are factors boosting this market’s revenue growth trajectory.

The increasing prevalence of various diseases such as cancer, inflammation, autoimmune disorders, and infections, among others, has fostered a greater demand for novel therapeutic approaches like immunotherapy, which uses the immune system to treat different diseases. These are also a few other prominent factors that are anticipated to continue to contribute to this market’s projected growth.
Recent Developments:

Novocell is a biotechnology company that has developed a novel technology that can be customized to select the T-cells needed to generate CD4+ T cell responses following vaccination. The company’s proprietary technology, NovoTCR, exploits the biology of the human immune system by turning an individual’s own T-cells into CD4+ memory cells.

Key Market Players:

This research report on the global TCR-based antibody market includes major company profiles such as:

• GlaxoSmithKline
• Adaptimmune Therapeutics PLC
• Celgene Corporation
• Immunocore
• Kuur Therapeutics Limited
• Lion TCR Pte. Ltd.
• Kite Pharma (A Gilead Sciences Company)
• Takara Bio Inc.
• Ziopharm Oncology Inc.
• Merck & Co. Inc.
• Juno Therapeutics
• Others.

Detail Segmentation:

Segmentation for Global TCR-Based Antibody Market based on Target Antigen, Indication, End-Users, and Region

Based on Target Antigen:

• NY-ESO-1
• p53
• WT-1
• EBv

Based on Indication:

• Bladder Cancer
• Multiple Myeloma
• Ovarian Cancer
• Nasopharyngeal Carcinoma
• Acute Myeloid Leukemia
• Sarcoma

Based on End-Users:

• Hospitals
• Specialized Clinics
• Pharma & Biotech Research Laboratories.
• Gene Therapy Centers

Based on Regions:

• North America
• Europe
• Asia Pacific
• South America
• MEA

For the TCR-Based Antibody Market research study, the following years have been considered to estimate the market size: